Established in 2004 in response to a growing need for pharmacokinetic (PK) analysis and modelling, the Clinical Pharmacology Analytical Core (CPAC) helps investigators by providing detailed information on drug interactions, quantification of drugs and metabolites, and protein binding of small molecules. CPAC services include preliminary determination of drug metabolism and metabolite identification for future use. These capabilities have been enhanced since acquiring the API 5500 Q-Trap instrument (described below). Once validated in the shared resource, chargebacks are calculated by the IUSCC administration. The process of rational drug design is built upon a strong foundation of biology, chemistry, in vivo pharmacology, and PK. Relevant PK and metabolism studies should be conducted in small animal models or in vitro systems before first drug administration in humans. This allows for the iterative process of implementing structural changes in the drug molecule to optimize the activity of the drug and its pharmacological and PK properties prior to moving to the more regulated and expensive clinical phase of drug development. PK plays an important role in the determination of drug action. The drug discovery process should provide a delicate balance between the chemistry, pharmacology, and PK of the drug. To coordinate these efforts, CPAC is now interacting closely with In Vivo Therapeutics (IVTC), Chemical Genomics, Center for Computational Biology and Bioinformatics, and other IUSCC shared resources. Over the past few years, CPAC and IVTC have worked together to generate data that help Pls better evaluate molecules developed within the IUSCC that show promise as novel cancer drugs. IVTC performs the live phase study {in vivo) and collects samples for CPAC to perform the kinetics. Both core leaders are directly involved in study design prior to project initiation. PK and metabolism data provide important information to guide drug design and treatment in pre-clinical drug discovery (bench) as well as in clinical drug development and treatment (bedside) with efforts focused on evaluation of toxicity and efficacy of new drug candidates. CPAC's state-of-the-art technology and expertise supports research and development of safe and more efficacious drug treatment for IUSCC investigators

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Indiana University-Purdue University at Indianapolis
United States
Zip Code
Hoggatt, Jonathan; Singh, Pratibha; Tate, Tiffany A et al. (2018) Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell. Cell 172:191-204.e10
Filley, Anna; Henriquez, Mario; Bhowmik, Tanmoy et al. (2018) Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas. J Neurooncol 137:469-479
Sishtla, Kamakshi; Pitt, Natalie; Shadmand, Mehdi et al. (2018) Observations on spontaneous tumor formation in mice overexpressing mitotic kinesin Kif14. Sci Rep 8:16152
Koh, Byunghee; Abdul Qayum, Amina; Srivastava, Rajneesh et al. (2018) A conserved enhancer regulates Il9 expression in multiple lineages. Nat Commun 9:4803
Reese, Michael J; Knapp, Deborah W; Anderson, Kimberly M et al. (2018) In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs. PLoS One 13:e0203517
Singh, Pratibha; Fukuda, Seiji; Liu, Liqiong et al. (2018) Survivin Is Required for Mouse and Human Bone Marrow Mesenchymal Stromal Cell Function. Stem Cells 36:123-129
Olivos 3rd, David J; Perrien, Daniel S; Hooker, Adam et al. (2018) The proto-oncogene function of Mdm2 in bone. J Cell Biochem 119:8830-8840
Shiue, Kevin; Cerra-Franco, Alberto; Shapiro, Ronald et al. (2018) Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. J Thorac Oncol 13:1549-1559
Liu, Yunhua; Xu, Hanchen; Van der Jeught, Kevin et al. (2018) Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. J Clin Invest 128:2951-2965
Pin, Fabrizio; Barreto, Rafael; Kitase, Yukiko et al. (2018) Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle 9:685-700

Showing the most recent 10 out of 256 publications